Clinical Trials Logo
  1. Home
  2. Glomerulonephritis
  3. NCT04349683

Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis

Glomerulonephritis Clinical Trial

Official title:
Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis：A Multicenter Randomized Controlled Clinical Trial

Clinical Trial Summary

This is a multicenter, double-blind randomized controlled study to assess the efficacy and safety of Jinshuibao for patients with CKD due to glomerulonephritis, with a planned follow-up of 48 weeks.

Clinical Trial Description

Previous studies have shown that cordyceps sinensis can act on several immune response pathways. Jinshuibao capsule, which is composed of fermented cordyceps sinensis powder (Cs-4) , has shown therapeutic effects in chronic kidney disease (CKD) according to small sample exploratory studies. Here, we conduct a prospective, double-blind randomized controlled study to assess the efficacy and safety of Jinshuibao for patients with CKD due to glomerulonephritis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04349683
Study type Interventional
Source Jemincare
Contact
Status Not yet recruiting
Phase Phase 4
Start date April 30, 2020
Completion date October 30, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT00001457 - Lamivudine for Chronic Hepatitis B Phase 2
Recruiting NCT05505955 - Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency Phase 1
Recruiting NCT01240564 - The Nephrotic Syndrome Study Network (NEPTUNE) N/A
Active, not recruiting NCT05174221 - A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy Phase 1
Completed NCT00426348 - A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Phase 4
Recruiting NCT04662723 - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Phase 4
Completed NCT02700516 - Recurrent Glomerulonephritis After Renal Transplantation N/A
Recruiting NCT00862693 - Calcitriol in the Treatment of Immunoglobulin A Nephropathy Phase 4
Completed NCT00983034 - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy N/A
Completed NCT00004990 - Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis Phase 2
Recruiting NCT04846010 - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 Phase 1/Phase 2
Terminated NCT04387448 - A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Phase 2
Terminated NCT04950114 - An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases Phase 2
Completed NCT00437463 - Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor Phase 3
Terminated NCT02523768 - Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment Phase 4
Completed NCT00106561 - Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney Phase 2/Phase 3
Completed NCT04733040 - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE) Phase 2
Completed NCT00001676 - Cyclophosphamide and Fludarabine to Treat Lupus Nephritis Phase 1
Recruiting NCT02063100 - Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis Phase 4
Completed NCT01093157 - A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy Phase 1/Phase 2